Distinct Signaling Events Downstream of mTOR Cooperate To Mediate the Effects of Amino Acids and Insulin on Initiation Factor 4E-Binding Proteins

REFERENCES

• Avruch, J., C. Belham, Q. Weng, K. Hara, and K. Yonezawa. 2001. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog. Mol. Subcell. Biol. 26:115–154.
   PubMedGoogle Scholar
• Berra, E., E. Benizri, A. Ginouves, V. Volmat, D. Roux, and J. Pouyssegur. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22:4082–4090.
   PubMed Web of Science ®Google Scholar
• Beugnet, A., X. Wang, and C. G. Proud. 2003. The TOR-signaling and RAIP motifs play distinct roles in the mTOR-dependent phosphorylation of initiation factor 4E-binding protein 1 in vivo. J. Biol. Chem. 278:40722.
   Google Scholar
• Browne, G. J., and C. G. Proud. 2004. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol. Cell. Biol. 24:2986–2997.
   PubMed Web of Science ®Google Scholar
• Brunn, G. J., C. C. Hudson, A. Sekulic, J. M. Williams, H. Hosoi, P. J. Houghton, J. C. Lawrence, and R. T. Abraham. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99–101.
   PubMed Web of Science ®Google Scholar
• Brunn, G. J., J. Williams, C. Sabers, G. Weiderrecht, J. C. Lawrence, and R. T. Abraham. 1996. Direct inhibition of the signalling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15:5256–5267.
   PubMed Web of Science ®Google Scholar
• Burnett, P. E., R. K. Barrow, N. A. Cohen, S. H. Snyder, and D. M. Sabatini. 1998. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95:1432–1437.
   PubMed Web of Science ®Google Scholar
• Campbell, L. E., X. Wang, and C. G. Proud. 1999. Nutrients differentially modulate multiple translation factors and their control by insulin. Biochem. J. 344:433–441.
   PubMedGoogle Scholar
• Choi, K.-M., L. P. McMahon, and J. C. Lawrence. 2003. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J. Biol. Chem. 278:19667–19673.
   PubMedGoogle Scholar
• De Benedetti, A., and J. R. Graff. 2004. eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199.
   PubMed Web of Science ®Google Scholar
• Diggle, T. A., S. K. Moule, M. B. Avison, A. Flynn, E. J. Foulstone, C. G. Proud, and R. M. Denton. 1996. Both rapamycin-sensitive and -insensitive pathways are involved in the phosphorylation of the initiation factor 4E binding protein (4E-BP1) in response to insulin in rat epididymal fat cells. Biochem. J. 316:447–453.
   PubMedGoogle Scholar
• Edinger, A. L., C. M. Linardic, G. G. Chiang, C. B. Thompson, and R. T. Abraham. 2003. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63:8451–8460.
   PubMed Web of Science ®Google Scholar
• Fattori, R., and T. Piva. 2003. Drug-eluting stents in vascular intervention. Lancet 361:247–249.
   PubMed Web of Science ®Google Scholar
• Ferguson, G., I. Mothe-Satney, and J. C. Lawrence, Jr. 2003. Ser-64 and Ser-111 in PHAS-I are dispensable for insulin-stimulated dissociation from eIF4E. J. Biol. Chem. 278:47459–47465.
   PubMedGoogle Scholar
• Ferrari, S., R. B. Pearson, M. Siegmann, S. C. Kozma, and G. Thomas. 1993. The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. J. Biol. Chem. 268:16091–16094.
   PubMedGoogle Scholar
• Fingar, D. C., and J. Blenis. 2004. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151–3171.
   PubMed Web of Science ®Google Scholar
• Fingar, D. C., C. J. Richardson, A. R. Tee, L. Cheatham, C. Tsou, and J. Blenis. 2004. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24:200–216.
   PubMed Web of Science ®Google Scholar
• Fletcher, C. M., A. M. McGuire, A.-C. Gingras, H. Li, H. Matsuo, N. Sonenberg, and G. Wagner. 1998. 4E binding proteins inhibit the translation factor eIF4E without folded structure. Biochemistry 37:9–15.
   PubMedGoogle Scholar
• Fox, H. L., P. T. Pham, S. R. Kimball, L. S. Jefferson, and C. J. Lynch. 1998. Amino acid effects on translational repressor 4E-BP1 are mediated primarily by L-leucine in isolated adipocytes. Am. J. Physiol. 44:C1232—C1238.
   Google Scholar
• Garami, A., F. J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, H. Stocker, S. C. Kozma, E. Hafen, J. L. Bos, and G. Thomas. 2003. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11:1457–1466.
   PubMed Web of Science ®Google Scholar
• Gingras, A.-C., S. P. Gygi, B. Raught, R. D. Polakiewicz, R. T. Abraham, M. F. Hoekstra, R. Aebersold, and N. Sonenberg. 1999. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13:1422–1437.
   PubMed Web of Science ®Google Scholar
• Gingras, A.-C., B. Raught, S. P. Gygi, A. Niedzwieka, M. Miron, S. K. Burley, R. D. Polakiewicz, A. Wyslouch-Cieczyska, R. Aebersold, and N. Sonenberg. 2001. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15:2852–2864.
   PubMed Web of Science ®Google Scholar
• Gingras, A.-C., B. Raught, and N. Sonenberg. 2001. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15:807–826.
   PubMed Web of Science ®Google Scholar
• Gross, J. D., N. J. Moerke, H. T. von der, A. A. Lugovskoy, A. B. Sachs, J. E. McCarthy, and G. Wagner. 2003. Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E. Cell 115:739–750.
   PubMed Web of Science ®Google Scholar
• Guba, M., P. von Breitenbuch, M. Steinbauer, G. Koehl, S. Flegel, M. Hornung, C. J. Bruns, C. Zuelke, S. Farkas, M. Anthuber, K. W. Jauch, and E. K. Geissler. 2002. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8:128–135.
   PubMed Web of Science ®Google Scholar
• Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177–189.
   PubMed Web of Science ®Google Scholar
• Hara, K., K. Yonezawa, Q.-P. Weng, M. T. Kozlowski, C. Belham, and J. Avruch. 1998. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF4E BP1 through a common effector mechanism. J. Biol. Chem. 273:14484–14494.
   PubMed Web of Science ®Google Scholar
• Harris, T. E., and J. C. Lawrence. 2003. TOR signaling. Science STKE 2003:15.
   Google Scholar
• Haystead, T. A. J., C. M. M. Haystead, C. Hu, T. A. Lin, and J. C. Lawrence. 1994. Phosphorylation of PHAS-I by MAP kinase. Identification of a site phosphorylated by MAP kinase in vitro and in response to insulin in rat adipocytes. J. Biol. Chem. 269:23185–23191.
   PubMed Web of Science ®Google Scholar
• Helliwell, S. B., P. Wagner, J. Kunz, M. Deuter-Reinhard, R. Henriquez, and M. N. Hall. 1994. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol. Biol. Cell 5:105–118.
   PubMed Web of Science ®Google Scholar
• Herbert, T. P., G. R. Kilhams, I. H. Batty, and C. G. Proud. 2000. Distinct signalling pathways mediate insulin and phorbol ester-stimulated eIF4F assembly and protein synthesis in HEK 293 cells. J. Biol. Chem. 275:11249–11256.
   PubMedGoogle Scholar
• Herbert, T. P., A. R. Tee, and C. G. Proud. 2002. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J. Biol. Chem. 277:11591–11596.
   PubMedGoogle Scholar
• Houghton, P. J., and S. Huang. 2004. mTOR as a target for cancer therapy. Curr. Topics Microbiol. Immunol. 279:339–359.
   PubMed Web of Science ®Google Scholar
• Inoki, K., Y. Li, T. Xu, and K. L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:1829–1834.
   PubMed Web of Science ®Google Scholar
• Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg, A. Hall, and M. N. Hall. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6:1122–1128.
   PubMed Web of Science ®Google Scholar
• Kim, D. H., D. Sarbassov, S. M. Ali, R. R. Latek, K. V. Guntur, H. Erdjument-Bromage, P. Tempst, and D. Sabatini. 2002. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11:895–904.
   Google Scholar
• Kim, D. H., D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–175.
   PubMed Web of Science ®Google Scholar
• Kudchodkar, S. B., Y. Yu, T. G. Maguire, and J. C. Alwine. 2004. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J. Virol. 78:11030–11039.
   PubMed Web of Science ®Google Scholar
• Kunz, J., R. Henriquez, U. Schneider, M. Deuter-Reinhard, N. R. Movva, and M. N. Hall. 1993. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73:585–596.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski, D. J. 2003. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 67:87–96.
   PubMed Web of Science ®Google Scholar
• Lawrence, J. C., and R. T. Abraham. 1997. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trends Biochem. Sci. 22:345–349.
   PubMedGoogle Scholar
• Leslie, N. R., A. Gray, I. Pass, E. A. Orchiston, and C. P. Downes. 2000. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Biochem. J. 346(Pt. 3):827–833.
   PubMedGoogle Scholar
• Lin, T. A., and J. C. Lawrence. 1996. Control of the translational regulators PHAS-I and PHAS-II by insulin and cAMP in 3T3-L1 adipocytes. J. Biol. Chem. 271:30199–30204.
   PubMedGoogle Scholar
• Loewith, R., E. Jacinto, S. Wullschleger, A. Lorberg, J. L. Crespo, D. Bonenfant, W. Oppliger, P. Jenoe, and M. N. Hall. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10:457–468.
   PubMed Web of Science ®Google Scholar
• MacDonald, A. S. 2003. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant. Proc. 35:201S—208S.
   PubMedGoogle Scholar
• Mamane, Y., E. Petroulakis, L. Rong, K. Yoshida, L. W. Ler, and N. Sonenberg. 2004. eIF4E-from translation to transformation. Oncogene 23:3172–3179.
   PubMed Web of Science ®Google Scholar
• Manning, B. D., and L. C. Cantley. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 28:573–576.
   PubMed Web of Science ®Google Scholar
• Manning, B. D., A. R. Tee, M. N. Logsdon, J. Blenis, and L. C. Cantley. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10:151–162.
   PubMed Web of Science ®Google Scholar
• McMahon, L. P., K. M. Choi, T. A. Lin, R. T. Abraham, and J. C. Lawrence, Jr. 2002. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol. Cell. Biol. 22:7428–7438.
   PubMedGoogle Scholar
• McManus, E. J., and D. R. Alessi. 2002. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat. Cell Biol. 4:E214—E216.
   Google Scholar
• Mothe-Satney, I., G. J. Brunn, L. P. McMahon, C. T. Capaldo, R. T. Abraham, and J. C. Lawrence. 2000. Mammalian target of rapamycin-dependent phosphorylation of PHAS-1 in four (S/T)P sites detected by phospho-specific antibodies. J. Biol. Chem. 275:33836–33843.
   PubMedGoogle Scholar
• Mothe-Satney, I., D. Yang, P. T. Fadden, A. J. Haystead, and J. C. Lawrence. 2000. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol. Cell. Biol. 20:3558–3567.
   PubMedGoogle Scholar
• Murakami, M., T. Ichisaka, M. Maeda, N. Oshiro, K. Hara, F. Edenhofer, H. Kiyama, K. Yonezawa, and S. Yamanaka. 2004. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24:6710–6718.
   PubMed Web of Science ®Google Scholar
• Myers, M. P., I. Pass, I. H. Batty, K. J. Van der, J. P. Stolarov, B. A. Hemmings, M. H. Wigler, C. P. Downes, and N. K. Tonks. 1998. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA 95:13513–13518.
   PubMed Web of Science ®Google Scholar
• Nojima, H., C. Tokunaga, S. Eguchi, N. Oshiro, S. Hidayat, K. Yoshino, K. Hara, J. Tanaka, J. Avruch, and K. Yonezawa. 2003. The mTOR partner, raptor, binds the mTOR substrates, p70 S6 kinase and 4E-BP1, through their TOS (TOR signaling) motifs. J. Biol. Chem. 278:15461–15464.
   PubMed Web of Science ®Google Scholar
• Oshiro, N., K. Yoshino, S. Hidayat, C. Tokunaga, K. Hara, S. Eguchi, J. Avruch, and K. Yonezawa. 2004. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9:359–366.
   PubMed Web of Science ®Google Scholar
• Patel, J., X. Wang, and C. G. Proud. 2001. Glucose exerts a permissive effect on the regulation of the initiation factor 4E binding protein 4E-BP1. Biochem. J. 358:497–503.
   PubMedGoogle Scholar
• Peterson, R. T., P. A. Beal, M. J. Comb, and S. L. Schreiber. 2000. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem. 275:7416–7423.
   PubMed Web of Science ®Google Scholar
• Price, N. T., S. F. Nakielny, S. J. Clark, and C. G. Proud. 1989. The two forms of the beta-subunit of initiation factor-2 from reticulocyte lysates arise from proteolytic degradation. Biochim. Biophys. Acta 1008:177–182.
   PubMedGoogle Scholar
• Proud, C. G. 2002. Regulation of mammalian translation factors by nutrients. Eur. J. Biochem. 269:5338–5349.
   PubMedGoogle Scholar
• Sarbassov, D., S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296–1302.
   PubMed Web of Science ®Google Scholar
• Schalm, S. S., and J. Blenis. 2002. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12:632–639.
   PubMed Web of Science ®Google Scholar
• Schalm, S. S., D. C. Fingar, D. M. Sabatini, and J. Blenis. 2003. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13:797–806.
   PubMed Web of Science ®Google Scholar
• Stern, B. D., M. Wilson, and R. Jagus. 1993. Use of nonreducing SDS-PAGE for monitoring renaturation of recombinant protein synthesis initiation factor, eIF-4 alpha. Protein Expr. Purif. 4:320–327.
   PubMed Web of Science ®Google Scholar
• Takahashi, T., K. Hara, H. Inoue, Y. Kawa, C. Tokunaga, S. Hidayat, K. Yoshino, Y. Kuroda, and K. Yonezawa. 2000. Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells 5:765–775.
   PubMed Web of Science ®Google Scholar
• Tang, X., L. Wang, C. G. Proud, and C. P. Downes. 2003. Muscarinic receptor-mediated activation of p70 S6 kinase 1 (S6K1) in 1321N1 astrocytoma cells: permissive role of phosphoinositide 3-kinase. Biochem. J. 374:137–143.
   PubMedGoogle Scholar
• Tee, A. R., D. C. Fingar, B. D. Manning, D. J. Kwiatkowski, L. C. Cantley, and J. Blenis. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA 99:13571–13576.
   PubMed Web of Science ®Google Scholar
• Tee, A. R., B. D. Manning, P. P. Roux, L. C. Cantley, and J. Blenis. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:1259–1268.
   PubMed Web of Science ®Google Scholar
• Tee, A. R., and C. G. Proud. 2000. DNA damage causes inactivation of translational regulators linked to mTOR signalling. Oncogene 19:3021–3031.
   PubMed Web of Science ®Google Scholar
• Tee, A. R., and C. G. Proud. 2002. Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Mol. Cell. Biol. 22:1674–1683.
   PubMed Web of Science ®Google Scholar
• Wang, L., and C. G. Proud. 2002. Ras/Erk signalling is required for regulation of translation factors linked to mTOR and protein synthesis by hypertrophic agents in cardiomyocytes. Circ. Res. 91:821–829.
   PubMed Web of Science ®Google Scholar
• Wang, X., L. E. Campbell, C. M. Miller, and C. G. Proud. 1998. Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem. J. 334:261–267.
   PubMed Web of Science ®Google Scholar
• Wang, X., W. Li, J.-L. Parra, A. Beugnet, and C. G. Proud. 2003. The C-terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol. Cell. Biol. 23:1546–1557.
   PubMed Web of Science ®Google Scholar
• Yang, D., G. J. Brunn, and J. C. Lawrence. 1999. Mutational analysis of sites in the translational regulator, PHAS-I, that are selectively phosphorylated by mTOR. FEBS Lett. 453:387–390.
   PubMedGoogle Scholar
• Yonezawa, K., K. I. Yoshino, C. Tokunaga, and K. Hara. 2004. Kinase activities associated with mTOR. Curr. Top. Microbiol. Immunol. 279:271–282.
   PubMedGoogle Scholar
• Zheng, X. F., D. Florentino, J. Chen, G. R. Crabtree, and S. L. Schreiber. 1995. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82:121–130.
   PubMed Web of Science ®Google Scholar
• Zhong, H., K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M. M. Georgescu, J. W. Simons, and G. L. Semenza. 2000. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:1541–1545.
   PubMed Web of Science ®Google Scholar
• Zhu, J., J. Wu, E. Frizell, S. L. Liu, R. Bashey, R. Rubin, P. Norton, and M. A. Zern. 1999. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117:1198–1204.
   PubMed Web of Science ®Google Scholar